(Q53371760)

13 May 2018

title

Identification and validation of a potent type II inhibitor of inactive polo-like kinase 1. (English)

1 reference

13 May 2018

3

Gisbert Schneider

1 reference

13 May 2018

2

Ewgenij Proschak

1 reference

13 May 2018

Sarah Keppner

1

1 reference

13 May 2018

Birgit Spänkuch

series ordinal

4

1 reference

13 May 2018

publication date

1 November 2009

1 reference

13 May 2018

published in

ChemMedChem

1 reference

13 May 2018

volume

4

1 reference

13 May 2018

issue

11

1 reference

13 May 2018

page(s)

1806-1809

1 reference

13 May 2018

Intravesical administration of small interfering RNA targeting PLK-1 successfully prevents the growth of bladder cancer.

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900338

Polo-like kinases: a team that plays throughout mitosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900338

7 January 2021

Induction and down-regulation of PLK, a human serine/threonine kinase expressed in proliferating cells and tumors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900338

7 January 2021

Targeting polo-like kinase 1 for cancer therapy.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900338

7 January 2021

Polo-like kinases and oncogenesis

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900338

7 January 2021

Polo-like kinase 1 phosphorylates cyclin B1 and targets it to the nucleus during prophase

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900338

7 January 2021

Cooperative phosphorylation including the activity of polo-like kinase 1 regulates the subcellular localization of cyclin B1.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900338

7 January 2021

Plk1 promotes nuclear translocation of human Cdc25C during prophase

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900338

7 January 2021

Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900338

7 January 2021

Polo-like kinase (Plk) 1: a novel target for the treatment of prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900338

7 January 2021

Antibody microinjection reveals an essential role for human polo-like kinase 1 (Plk1) in the functional maturation of mitotic centrosomes

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900338

7 January 2021

Effect of RNA silencing of polo-like kinase-1 (PLK1) on apoptosis and spindle formation in human cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900338

7 January 2021

Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900338

7 January 2021

Cancer inhibition in nude mice after systemic application of U6 promoter-driven short hairpin RNAs against PLK1.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900338

7 January 2021

The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900338

7 January 2021

BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900338

7 January 2021

ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900338

7 January 2021

Rational design of inhibitors that bind to inactive kinase conformations

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900338

7 January 2021

Virtual screening and its integration with modern drug design technologies.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900338

7 January 2021

Ligand-supported homology modeling of g-protein-coupled receptor sites: models sufficient for successful virtual screening

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900338

7 January 2021

Discovery of novel human histamine H4 receptor ligands by large-scale structure-based virtual screening

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900338

7 January 2021

The discovery of Kv1.5 blockers as a case study for the application of virtual screening approaches

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900338

7 January 2021

Structure-based drug discovery using GPCR homology modeling: successful virtual screening for antagonists of the alpha1A adrenergic receptor

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900338

7 January 2021

Structure of the catalytic domain of human polo-like kinase 1

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900338

7 January 2021

Improved protein-ligand docking using GOLD

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900338

7 January 2021

Identifiers

DOI

10.1002/CMDC.200900338

1 reference

13 May 2018

release_h4o54wx36rdwbfdoo2z433ealq

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/h4o54wx36rdwbfdoo2z433ealq

24 November 2022

mapped directly with Wikidata item

PubMed ID

19746360

1 reference

13 May 2018